Effects of rosastatin combined with Danggui Buxue Tang on expressions of AR and NR3C2

doi:10.19803/j.1672-8629.20240067

Abstract

Abstract: Objective To predict the mechanism of roxadustat combined with Danggui Buxue Tang against renal anemia (RA) based on network pharmacology, and to verify the result via animal experiments. Methods The target proteins and signaling pathways were retrieved from PharmMapper, TCMSP, STRING, GeneCards, OMIM and DAVID database. The potential targets of roxadustat combined with Danggui Buxue Tang in treating RA were explored. A “drug-target-pathway” model was established to predict possible biological pathways. Subsequently, rat experiments were conducted to validate the main targets. Results Network pharmacology research found that the combination of roxadustat and Danggui Buxue Tang mainly exerted therapeutic effects on renal anemia through four common protein targets, namely NR3C2, AR, NR1I3, and RUNX1T1, as well as through 16 common signaling pathways such as PI3K-Akt pathway. The combination of roxadustat and Danggui Buxue Tang could upregulate the expression of target protein AR but inhibit the expression of target protein NR3C2 to exert its effects. Conclusion The combination of roxadustat and Danggui Buxue Tang can improve inflammation and oxidative stress in the body by inhibiting the expression of NR3C2 and upregulating the expression of AR, thereby exerting a therapeutic effect on renal anemia.

Key words: roxadustat, Danggui Buxue Tang, renal anemia, network pharmacology, rat

CLC Number:

R973.3

ZHANG Kaihua, LIU Dingwei, FU Changhai, SUN Xuelin, MIN Xianjun. Effects of rosastatin combined with Danggui Buxue Tang on expressions of AR and NR3C2[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 871-877.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240067

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I8/871

References

[1] HAALEN HV, SLOANDl J, MOON R, et al.Drug treatment patterns and work productivity in chronic kidney disease patients with anemia in China: cross sectional analysis of real-world data[J]. Kidney Research and Clinical Practice, 2020, 39(3): 318-333.
[2] BORAWSKI B, MALYSZKO JS, KWIATKOWSKA, et al. Current status of renal anemia pharmacotherapy-What can we offer today[J]. Journal of Clinical Medicine, 2021, 10(18): 4149.
[3] ASCHEMEYER S, QIAO B, STEFANOVA D, et al.Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin[J]. Blood, 2018, 131(8): 899-910.
[4] LIN MZ,LI X.Clinical guidance significance of oxidative stress evaluation in the diagnosis of digestive tract tumors[J]. World Journal of Chinese Digestion(世界华人消化杂志), 2014(24): 3718-3721.
[5] WEN LB, WEI MH.Current status of traditional Chinese and western medicine in the treatment of tumor-related anemia[J]. Internal Medicine(内科), 2021, 16(5): 630-632, 673.
[6] Clinical Chemotherapy Committee of Chinese Anti-Cancer Association, Tumor Supportive Care Committee of Chinese Anti-Cancer Association. Expert consensus on the diagnosis and treatment of chemotherapy-related anemia in China (2019 Edition)[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2019, 46(17): 869-875.
[7] LI ZL, TU Y, LIU BC.Treatment of renal anemia with roxadustat: advantages and achievement[J]. Kidney Diseases (Basel, Switzerland), 2020, 6(2): 65-73.
[8] CHEN N, HAO C, PENG X, et al.Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. The New England Journal of Medicine, 2019, 381(11): 1001-1010.
[9] LIU J, YANG F, WAHEED Y, et al.The role of roxadustat in chronic kidney disease patients complicated with anemia[J]. The Korean Journal of Internal Medicine, 2023, 38(2): 147-156.
[10] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China,Volume I(中华人民共和国药典一部)[M]. Beijing: China Medical Science Press, 2020: 1-616.
[11] GAO H, YUAN J, CHENG XH.Angelica Buxue decoction combined with erythropoietin in the treatment of renal anemia in 34 cases[J]. Henan Traditional Chinese Medicine(河南中医), 2014, 34(3): 549-550.
[12] LU H, XIA MQ, WANG H, et al.Clinical observation of Angelica sinensis Buxue decoction combined with levocarnitine in the treatment of renal anemia[J]. World Chinese Medicine(世界中医药), 2022, 17(1): 108-111.
[13] CHENG MY.Clinical observation on the effect of Shengxuening tablets combined with roxastea on renal anemia and residual kidney function in peritoneal dialysis patients[D]. Wuhan: Hubei University of Chinese Medicine(湖北中医药大学), 2023
[14] WANG QL.Effect of roxadustat combined with Shengxuening tablets on patients with renal anemia on hemodialysis[J]. Medical Theory and Practice(医学理论与实践), 2023, 36(7): 1160-1163
[15] FU CL, LU Y, CHEN SY, et al.Mechanism of action of hemp in the treatment of rheumatoid arthritis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(2): 171-176.
[16] MA LL, LI J, GENG F, et al.Mechanism of action of nephritis anti-decay liquid to improve renal anemia in rats with chronic renal failure[J]. Chinese Journal of Traditional Chinese Medicine(中华中医药杂志), 2022, 37(7): 3806-3810.
[17] WU YS, WAN Q, SHI LQ, et al.Comparison of two methods for establishing a rat model of chronic renal failure complicated with renal anemia[J]. Journal of Bengbu Medical College(蚌埠医学院学报), 2017, 42(10): 1293-1297, 1301.
[18] ZHANG H, WANG XJ, LIU MQ, et al.Discussion on the dosage of intragastric administration in experimental animals containing traditional Chinese medicine[J]. Jilin Traditional Chinese Medicine(吉林中医药), 2015, 35(6): 623-625.
[19] LIU L, XU L, WANG YJ, et al.Study on the clinical efficacy of Shengxuening tablets combined with roxadustat in the treatment of renal anemia[J]. Chinese Journal of Traditional Chinese Medicine(中华中医药学刊), 2022, 40(9): 247-250.
[20] TIAN L, ZHAO Z, XIE L, et al.MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway[J]. Oncotarget, 2018, 9(4): 4886-4896.
[21] SU H, WAN C, SONG A, et al.Oxidative Stress and renal fibrosis:mechanisms and therapies[J]. Advances in Experimental Medicine and Biology, 2019, 1165: 585-604.
[22] LIE BF, CHENG F, DUAN TT, et al.Effect of Astragalus san pellets on PI3K/Akt/mTOR pathway and autophagy in the kidney of rats with diabetic nephropathy[J]. Chinese Journal of Experimental Pharmaceutics(中国实验方剂学杂志), 2022, 28(7): 11-17.
[23] IRAN NA, NEMATBAKHSH M, ESHRAGHI JF, et al.Preventive role of estradiol on kidney injury induced by renal ischemia-reperfusion in male and female rats[J]. International Journal of Preventive Medicine, 2015, 6: 22.
[24] ROMEJKO K, RYMARZ A, SADOWNIK H, et al.Testosterone deficiency as one of the major endocrine disorders in chronic kidney disease[J]. Nutrients, 2022, 14(16): 3438.
[25] DHINDSA S, GHANIM H, BATRA M, et al.Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes[J]. Clinical Endocrinology, 2016, 85(5): 772-780.
[26] KETCHEM JM, BOWMAN EJ, ISALES CM.Male sex hormones, aging, and inflammation[J]. Biogerontology, 2023, 24(1): 1-25.
[27] OAKLEY RH, CRUZ TD, HE B, et al. Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice[J]. Science Signaling, 2019, 12(577): eaau9685.
[28] MAN JJ, LU Q, MOSS ME, et al.Myeloid mineralocorticoid receptor transcriptionally regulates P-selectin glycoprotein ligand-1 and promotes monocyte trafficking and atherosclerosis[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41(11): 2740-2755.
[29] COSTA E, PEREIRA BJ, ROCHA PP, et al.Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients[J]. American Journal of Nephrology, 2008, 28(4): 677-683.
[30] GALE DP, HARTEN SK, REID CD, et al.Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation[J]. Blood, 2008, 112(3): 919-921.
[31] SCHOMIG M, EISENHARDT A, RITZ E.The microinflammatory state of uremia[J]. Blood Purification, 2000, 18(4): 327-332.
[32] OWEN WF, LOWRIE EG.C-reactive protein as an outcome predictor for maintenance hemodialysis patients[J]. Kidney International, 1998, 54(2): 627-636.
[33] SHU JL, SUN BG, LI H, et al.Comparison of different vascular access on microinflammatory factors and renal anemia in maintenance hemodialysis patients[J]. Chinese Journal of Integrative Medicine Nephrology(中国中西医结合肾病杂志), 2015, 16(6): 535-536.
[34] ZHAO XL.Multivariate analysis of renal anemia in patients on maintenance hemodialysis[J]. Doctor(名医), 2023(13): 93-95.
[35] PANG HY.Research advances in androgens and their receptors in chronic kidney disease-associated vascular calcification[J]. International Journal of Endocrinology and Metabolism(国际内分泌代谢杂志), 2022, 42(5): 387-390, 400.
[36] WANG L.Use of mineralocorticoid receptor antagonists in the treatment of chronic kidney disease[J]. Journal of Nephrology and Dialysis Kidney Transplantation(肾脏病与透析肾移植杂志), 2021, 30(5): 447-448.